Gluco-metabolic response to exogenous oxytocin in totally pancreatectomized patients and healthy individuals

• Published in: Peptides (New York, N.Y. : 1980) Vol. 179; p. 171242
• Main Authors: Kliim-Hansen, Vivian, Gether, Ida M., Juel, Caroline T.-B., Ellegaard, Anne-Marie, Pedersen, Miriam G., Hartmann, Bolette, Wewer Albrechtsen, Nicolai J., Holst, Jens J., Lund, Asger B., Gasbjerg, Lærke S., Knop, Filip K.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2024
• Subjects: Adult; Aged; Blood Glucose - metabolism; C-Peptide - blood; C-Peptide - metabolism; Female; Gastric Inhibitory Polypeptide - blood; Gastric Inhibitory Polypeptide - metabolism; Glucagon; Glucagon - blood; Glucagon - metabolism; Glucagon-like peptide 1 (GLP-1); Glucagon-Like Peptide 1 - blood; Glucagon-Like Peptide 1 - metabolism; Glucose metabolism; Humans; Insulin - blood; Insulin - metabolism; Male; Middle Aged; Oxytocin; Oxytocin - administration & dosage; Oxytocin - blood; Oxytocin - metabolism; Oxytocin - pharmacology; Pancreatectomy; Total pancreatectomy; GLP-1; Oxytocin; Glucagon; PX; BsAUC; Glucagon-like peptide 1 (GLP-1); IU; GIP; Glucose metabolism; CTRL; Total pancreatectomy; ANOVA; SEM; HbA1c; BMI; ELISA
• ISSN: 0196-9781; 1873-5169; 1873-5169
• DOI: 10.1016/j.peptides.2024.171242

Oxytocin has been proposed to possess glucose-stabilizing effects through the release of insulin and glucagon from the pancreas. Also, exogenous oxytocin has been shown to stimulate extrapancreatic glucagon secretion in depancreatized dogs. Here, we investigated the effect of exogenous oxytocin on circulating levels of pancreatic and gut-derived glucose-stabilizing hormones (insulin [measured as C-peptide], glucagon, glucagon-like peptide 1 [GLP-1], and glucose-dependent insulinotropic polypeptide). We studied nine pancreatectomized (PX) patients and nine healthy controls (CTRLs) (matched on age and body mass index) before, during, and after an intravenous infusion of 10 IU of oxytocin administered over 12 min. Oxytocin did not increase plasma glucagon levels, nor induce any changes in plasma glucose, C-peptide, or GIP in any of the groups. Oxytocin decreased plasma glucagon levels by 19 ± 10 % in CTRLs (from 2.0 ± 0.5 [mean ± SEM] to 1.3 ± 0.2 pmol/l, P = 0.0025) and increased GLP-1 by 42 ± 22 % in PX patients (from 9.0 ± 1.0–12.7 ± 1.0 pmol/l, P = 0.0003). Fasting plasma glucose levels were higher in PX patients compared with CTRLs (13.1 ± 1.1 vs. 5.1 ± 0.1 mmol/l, P < 0.0001). In conclusion, the present findings do not support pancreas-mediated glucose-stabilizing effects of acute oxytocin administration in humans and warrant further investigation of oxytocin’s gluco-metabolic effects. •The effect of oxytocin on gluco-regulatory hormones in humans is scarcely described.•Oxytocin stimulates extra-pancreatic glucagon secretion in depancreatized dogs.•Here, oxytocin was neither glucagonotropic nor insulinotropic in healthy individuals.•In pancreatectomized patients, oxytocin increased levels of glucagon-like peptide 1.